SK284839B6 - Použitie miltefozínu na výrobu lieku a farmaceutická kombinácia na liečenie leishmanózy - Google Patents

Použitie miltefozínu na výrobu lieku a farmaceutická kombinácia na liečenie leishmanózy Download PDF

Info

Publication number: SK284839B6
Authority: SK; Slovakia
Prior art keywords: miltefosine; active ingredient; use according; leishmaniasis; dose
Prior art date: 1998-01-22

Application number

SK986-2000A

Other languages

English (en)

Slovak (sk)

Other versions

SK9862000A3 (en

Inventor

J�Rgen Engel

Werner Sarlikiotis

Thomas Klenner

Peter Hilgard

Dieter Sauerbier

Eckhard Milsmann

Original Assignee

Zentaris Gmbh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-01-22

Filing date

1998-01-22

Publication date

2005-12-01

1998-01-22 Application filed by Zentaris Gmbh filed Critical Zentaris Gmbh

2000-11-07 Publication of SK9862000A3 publication Critical patent/SK9862000A3/sk

2005-12-01 Publication of SK284839B6 publication Critical patent/SK284839B6/sk

Links

229960003775 miltefosine Drugs 0.000 title claims abstract description 110
PQLXHQMOHUQAKB-UHFFFAOYSA-N miltefosine Chemical compound CCCCCCCCCCCCCCCCOP([O-])(=O)OCC[N+](C)(C)C PQLXHQMOHUQAKB-UHFFFAOYSA-N 0.000 title claims abstract description 109
239000003814 drug Substances 0.000 title claims abstract description 10
238000004519 manufacturing process Methods 0.000 title claims description 9
239000008194 pharmaceutical composition Substances 0.000 claims abstract description 29
208000004554 Leishmaniasis Diseases 0.000 claims abstract description 28
239000004480 active ingredient Substances 0.000 claims abstract description 28
230000003474 anti-emetic effect Effects 0.000 claims description 10
239000002111 antiemetic agent Substances 0.000 claims description 10
239000003793 antidiarrheal agent Substances 0.000 claims description 9
238000012423 maintenance Methods 0.000 claims description 5
241000124008 Mammalia Species 0.000 claims description 4
230000009278 visceral effect Effects 0.000 claims description 4
241000282472 Canis lupus familiaris Species 0.000 claims description 3
241000699800 Cricetinae Species 0.000 claims description 3
241000283984 Rodentia Species 0.000 claims description 3
230000037396 body weight Effects 0.000 claims description 3
238000002360 preparation method Methods 0.000 abstract description 9
230000001142 anti-diarrhea Effects 0.000 abstract 2
229940124537 antidiarrhoeal agent Drugs 0.000 abstract 2
239000000203 mixture Substances 0.000 description 55
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 30
239000002775 capsule Substances 0.000 description 29
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 25
239000003826 tablet Substances 0.000 description 23
239000000945 filler Substances 0.000 description 22
239000007787 solid Substances 0.000 description 17
239000000454 talc Substances 0.000 description 16
235000012222 talc Nutrition 0.000 description 16
229910052623 talc Inorganic materials 0.000 description 16
235000019359 magnesium stearate Nutrition 0.000 description 15
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 14
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 14
229920000168 Microcrystalline cellulose Polymers 0.000 description 14
239000003795 chemical substances by application Substances 0.000 description 14
239000008101 lactose Substances 0.000 description 14
239000008108 microcrystalline cellulose Substances 0.000 description 14
229940016286 microcrystalline cellulose Drugs 0.000 description 14
235000019813 microcrystalline cellulose Nutrition 0.000 description 14
239000004094 surface-active agent Substances 0.000 description 13
-1 Aerosil® V200 Chemical compound 0.000 description 10
108010010803 Gelatin Proteins 0.000 description 9
239000008273 gelatin Substances 0.000 description 9
229920000159 gelatin Polymers 0.000 description 9
235000019322 gelatine Nutrition 0.000 description 9
235000011852 gelatine desserts Nutrition 0.000 description 9
239000000377 silicon dioxide Substances 0.000 description 9
235000010980 cellulose Nutrition 0.000 description 8
229920002678 cellulose Polymers 0.000 description 8
239000001913 cellulose Substances 0.000 description 8
239000007903 gelatin capsule Substances 0.000 description 8
239000000314 lubricant Substances 0.000 description 8
229920002472 Starch Polymers 0.000 description 7
239000007938 effervescent tablet Substances 0.000 description 7
238000000034 method Methods 0.000 description 7
235000019698 starch Nutrition 0.000 description 7
239000004615 ingredient Substances 0.000 description 6
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 6
229920000036 polyvinylpyrrolidone Polymers 0.000 description 6
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical class OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 5
239000008119 colloidal silica Substances 0.000 description 5
239000001267 polyvinylpyrrolidone Substances 0.000 description 5
229940032147 starch Drugs 0.000 description 5
239000008107 starch Substances 0.000 description 5
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
VTYYLEPIZMXCLO-UHFFFAOYSA-L calcium carbonate Substances [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical class [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 4
125000004432 carbon atom Chemical group C* 0.000 description 4
MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 4
238000002156 mixing Methods 0.000 description 4
229920000151 polyglycol Polymers 0.000 description 4
239000010695 polyglycol Substances 0.000 description 4
238000005303 weighing Methods 0.000 description 4
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
206010011668 Cutaneous leishmaniasis Diseases 0.000 description 3
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 3
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
229930195725 Mannitol Natural products 0.000 description 3
241001465754 Metazoa Species 0.000 description 3
229920000881 Modified starch Polymers 0.000 description 3
206010047700 Vomiting Diseases 0.000 description 3
239000002253 acid Substances 0.000 description 3
239000000654 additive Substances 0.000 description 3
235000010443 alginic acid Nutrition 0.000 description 3
229920000615 alginic acid Polymers 0.000 description 3
229910052787 antimony Inorganic materials 0.000 description 3
WATWJIUSRGPENY-UHFFFAOYSA-N antimony atom Chemical compound [Sb] WATWJIUSRGPENY-UHFFFAOYSA-N 0.000 description 3
229910000389 calcium phosphate Inorganic materials 0.000 description 3
229940079593 drug Drugs 0.000 description 3
238000005516 engineering process Methods 0.000 description 3
235000003599 food sweetener Nutrition 0.000 description 3
239000008187 granular material Substances 0.000 description 3
239000000594 mannitol Substances 0.000 description 3
235000010355 mannitol Nutrition 0.000 description 3
235000019426 modified starch Nutrition 0.000 description 3
239000008203 oral pharmaceutical composition Substances 0.000 description 3
235000010987 pectin Nutrition 0.000 description 3
239000001814 pectin Substances 0.000 description 3
229920001277 pectin Polymers 0.000 description 3
235000019204 saccharin Nutrition 0.000 description 3
CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 3
229940081974 saccharin Drugs 0.000 description 3
239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 3
239000002904 solvent Substances 0.000 description 3
239000000600 sorbitol Substances 0.000 description 3
235000010356 sorbitol Nutrition 0.000 description 3
210000000952 spleen Anatomy 0.000 description 3
150000005846 sugar alcohols Chemical class 0.000 description 3
239000003765 sweetening agent Substances 0.000 description 3
230000008673 vomiting Effects 0.000 description 3
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
229910002012 Aerosil® Inorganic materials 0.000 description 2
BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 2
BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 2
229920002261 Corn starch Polymers 0.000 description 2
206010012735 Diarrhoea Diseases 0.000 description 2
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
229930091371 Fructose Natural products 0.000 description 2
239000005715 Fructose Substances 0.000 description 2
RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Chemical compound CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
239000004368 Modified starch Substances 0.000 description 2
CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
240000006394 Sorghum bicolor Species 0.000 description 2
235000021355 Stearic acid Nutrition 0.000 description 2
235000019486 Sunflower oil Nutrition 0.000 description 2
206010047505 Visceral leishmaniasis Diseases 0.000 description 2
208000026802 afebrile Diseases 0.000 description 2
229960004543 anhydrous citric acid Drugs 0.000 description 2
229940125683 antiemetic agent Drugs 0.000 description 2
SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
239000008280 blood Substances 0.000 description 2
210000004369 blood Anatomy 0.000 description 2
210000001185 bone marrow Anatomy 0.000 description 2
YYRMJZQKEFZXMX-UHFFFAOYSA-L calcium bis(dihydrogenphosphate) Chemical compound [Ca+2].OP(O)([O-])=O.OP(O)([O-])=O YYRMJZQKEFZXMX-UHFFFAOYSA-L 0.000 description 2
235000010216 calcium carbonate Nutrition 0.000 description 2
FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 2
239000001506 calcium phosphate Substances 0.000 description 2
235000011010 calcium phosphates Nutrition 0.000 description 2
235000013539 calcium stearate Nutrition 0.000 description 2
239000008116 calcium stearate Substances 0.000 description 2
239000000969 carrier Substances 0.000 description 2
229920003086 cellulose ether Polymers 0.000 description 2
150000001875 compounds Chemical class 0.000 description 2
238000001816 cooling Methods 0.000 description 2
239000008120 corn starch Substances 0.000 description 2
239000013078 crystal Substances 0.000 description 2
239000003085 diluting agent Substances 0.000 description 2
201000010099 disease Diseases 0.000 description 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
239000007884 disintegrant Substances 0.000 description 2
POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 2
238000001035 drying Methods 0.000 description 2
238000011049 filling Methods 0.000 description 2
150000002334 glycols Chemical class 0.000 description 2
150000008282 halocarbons Chemical class 0.000 description 2
BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
238000002844 melting Methods 0.000 description 2
230000008018 melting Effects 0.000 description 2
235000019691 monocalcium phosphate Nutrition 0.000 description 2
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
239000003921 oil Substances 0.000 description 2
235000019198 oils Nutrition 0.000 description 2
239000000546 pharmaceutical excipient Substances 0.000 description 2
229920006395 saturated elastomer Polymers 0.000 description 2
235000003441 saturated fatty acids Nutrition 0.000 description 2
229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
235000017557 sodium bicarbonate Nutrition 0.000 description 2
229920003109 sodium starch glycolate Polymers 0.000 description 2
239000008109 sodium starch glycolate Substances 0.000 description 2
229940079832 sodium starch glycolate Drugs 0.000 description 2
239000007962 solid dispersion Substances 0.000 description 2
239000008117 stearic acid Substances 0.000 description 2
235000000346 sugar Nutrition 0.000 description 2
239000002600 sunflower oil Substances 0.000 description 2
238000012360 testing method Methods 0.000 description 2
HLZKNKRTKFSKGZ-UHFFFAOYSA-N tetradecan-1-ol Chemical compound CCCCCCCCCCCCCCO HLZKNKRTKFSKGZ-UHFFFAOYSA-N 0.000 description 2
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical class [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 1
102000035037 5-HT3 receptors Human genes 0.000 description 1
108091005477 5-HT3 receptors Proteins 0.000 description 1
KSEYRUGYKHXGFW-UHFFFAOYSA-N 6-methoxy-N-[(1-prop-2-enyl-2-pyrrolidinyl)methyl]-2H-benzotriazole-5-carboxamide Chemical compound COC1=CC2=NNN=C2C=C1C(=O)NCC1CCCN1CC=C KSEYRUGYKHXGFW-UHFFFAOYSA-N 0.000 description 1
244000215068 Acacia senegal Species 0.000 description 1
WBZFUFAFFUEMEI-UHFFFAOYSA-M Acesulfame k Chemical compound [K+].CC1=CC(=O)[N-]S(=O)(=O)O1 WBZFUFAFFUEMEI-UHFFFAOYSA-M 0.000 description 1
206010001986 Amoebic dysentery Diseases 0.000 description 1
240000002470 Amphicarpaea bracteata Species 0.000 description 1
229920000856 Amylose Polymers 0.000 description 1
244000099147 Ananas comosus Species 0.000 description 1
235000007119 Ananas comosus Nutrition 0.000 description 1
108010011485 Aspartame Proteins 0.000 description 1
241001132374 Asta Species 0.000 description 1
241000416162 Astragalus gummifer Species 0.000 description 1
241000167854 Bourreria succulenta Species 0.000 description 1
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
235000005979 Citrus limon Nutrition 0.000 description 1
244000131522 Citrus pyriformis Species 0.000 description 1
240000000560 Citrus x paradisi Species 0.000 description 1
235000016795 Cola Nutrition 0.000 description 1
241001634499 Cola Species 0.000 description 1
235000011824 Cola pachycarpa Nutrition 0.000 description 1
229920002785 Croscarmellose sodium Polymers 0.000 description 1
229920000858 Cyclodextrin Polymers 0.000 description 1
CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
241000402754 Erythranthe moschata Species 0.000 description 1
208000005577 Gastroenteritis Diseases 0.000 description 1
229920000084 Gum arabic Polymers 0.000 description 1
241000238631 Hexapoda Species 0.000 description 1
241000282412 Homo Species 0.000 description 1
206010022678 Intestinal infections Diseases 0.000 description 1
239000005639 Lauric acid Substances 0.000 description 1
241000222722 Leishmania <genus> Species 0.000 description 1
241000220225 Malus Species 0.000 description 1
235000011430 Malus pumila Nutrition 0.000 description 1
235000015103 Malus silvestris Nutrition 0.000 description 1
FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
208000030852 Parasitic disease Diseases 0.000 description 1
235000019483 Peanut oil Nutrition 0.000 description 1
244000018633 Prunus armeniaca Species 0.000 description 1
235000009827 Prunus armeniaca Nutrition 0.000 description 1
208000001647 Renal Insufficiency Diseases 0.000 description 1
240000007651 Rubus glaucus Species 0.000 description 1
235000011034 Rubus glaucus Nutrition 0.000 description 1
235000009122 Rubus idaeus Nutrition 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
244000299461 Theobroma cacao Species 0.000 description 1
201000005485 Toxoplasmosis Diseases 0.000 description 1
229920001615 Tragacanth Polymers 0.000 description 1
102000003929 Transaminases Human genes 0.000 description 1
108090000340 Transaminases Proteins 0.000 description 1
208000025865 Ulcer Diseases 0.000 description 1
238000006887 Ullmann reaction Methods 0.000 description 1
235000009499 Vanilla fragrans Nutrition 0.000 description 1
244000263375 Vanilla tahitensis Species 0.000 description 1
235000012036 Vanilla tahitensis Nutrition 0.000 description 1
TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
235000010489 acacia gum Nutrition 0.000 description 1
239000000205 acacia gum Substances 0.000 description 1
235000010358 acesulfame potassium Nutrition 0.000 description 1
239000000619 acesulfame-K Substances 0.000 description 1
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
210000000577 adipose tissue Anatomy 0.000 description 1
150000001298 alcohols Chemical class 0.000 description 1
239000000783 alginic acid Substances 0.000 description 1
229960001126 alginic acid Drugs 0.000 description 1
125000001931 aliphatic group Chemical group 0.000 description 1
229960003687 alizapride Drugs 0.000 description 1
CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 1
229940063655 aluminum stearate Drugs 0.000 description 1
230000000181 anti-adherent effect Effects 0.000 description 1
230000000118 anti-neoplastic effect Effects 0.000 description 1
239000003911 antiadherent Substances 0.000 description 1
229940125714 antidiarrheal agent Drugs 0.000 description 1
239000000739 antihistaminic agent Chemical class 0.000 description 1
229940125715 antihistaminic agent Drugs 0.000 description 1
ZDINGUUTWDGGFF-UHFFFAOYSA-N antimony(5+) Chemical compound [Sb+5] ZDINGUUTWDGGFF-UHFFFAOYSA-N 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
125000003118 aryl group Chemical group 0.000 description 1
239000000605 aspartame Substances 0.000 description 1
235000010357 aspartame Nutrition 0.000 description 1
IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
229960003438 aspartame Drugs 0.000 description 1
201000008680 babesiosis Diseases 0.000 description 1
OGBUMNBNEWYMNJ-UHFFFAOYSA-N batilol Chemical compound CCCCCCCCCCCCCCCCCCOCC(O)CO OGBUMNBNEWYMNJ-UHFFFAOYSA-N 0.000 description 1
229940054066 benzamide antipsychotics Drugs 0.000 description 1
150000003936 benzamides Chemical class 0.000 description 1
229940049706 benzodiazepine Drugs 0.000 description 1
150000001557 benzodiazepines Chemical class 0.000 description 1
229960002903 benzyl benzoate Drugs 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
229910000019 calcium carbonate Inorganic materials 0.000 description 1
OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical class [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 1
235000011132 calcium sulphate Nutrition 0.000 description 1
230000000711 cancerogenic effect Effects 0.000 description 1
229930003827 cannabinoid Natural products 0.000 description 1
239000003557 cannabinoid Substances 0.000 description 1
229940065144 cannabinoids Drugs 0.000 description 1
239000001768 carboxy methyl cellulose Substances 0.000 description 1
235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
231100000315 carcinogenic Toxicity 0.000 description 1
239000005018 casein Substances 0.000 description 1
BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
235000021240 caseins Nutrition 0.000 description 1
210000004027 cell Anatomy 0.000 description 1
229960000541 cetyl alcohol Drugs 0.000 description 1
235000019693 cherries Nutrition 0.000 description 1
239000007910 chewable tablet Substances 0.000 description 1
235000019219 chocolate Nutrition 0.000 description 1
239000003240 coconut oil Substances 0.000 description 1
235000019864 coconut oil Nutrition 0.000 description 1
235000019516 cod Nutrition 0.000 description 1
238000007906 compression Methods 0.000 description 1
230000006835 compression Effects 0.000 description 1
239000012050 conventional carrier Substances 0.000 description 1
229920001577 copolymer Polymers 0.000 description 1
239000003246 corticosteroid Chemical class 0.000 description 1
229960001334 corticosteroids Drugs 0.000 description 1
239000002537 cosmetic Substances 0.000 description 1
235000019968 cyclamic acid and its sodium salt Nutrition 0.000 description 1
229940097362 cyclodextrins Drugs 0.000 description 1
230000018044 dehydration Effects 0.000 description 1
238000006297 dehydration reaction Methods 0.000 description 1
238000011161 development Methods 0.000 description 1
239000008121 dextrose Substances 0.000 description 1
235000019700 dicalcium phosphate Nutrition 0.000 description 1
229940095079 dicalcium phosphate anhydrous Drugs 0.000 description 1
208000000498 diffuse cutaneous leishmaniasis Diseases 0.000 description 1
235000013870 dimethyl polysiloxane Nutrition 0.000 description 1
150000004862 dioxolanes Chemical class 0.000 description 1
229960001253 domperidone Drugs 0.000 description 1
FGXWKSZFVQUSTL-UHFFFAOYSA-N domperidone Chemical compound C12=CC=CC=C2NC(=O)N1CCCN(CC1)CCC1N1C2=CC=C(Cl)C=C2NC1=O FGXWKSZFVQUSTL-UHFFFAOYSA-N 0.000 description 1
230000000694 effects Effects 0.000 description 1
239000007911 effervescent powder Substances 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
125000005912 ethyl carbonate group Chemical class 0.000 description 1
238000001704 evaporation Methods 0.000 description 1
238000004880 explosion Methods 0.000 description 1
150000002191 fatty alcohols Chemical class 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
235000019634 flavors Nutrition 0.000 description 1
235000013305 food Nutrition 0.000 description 1
238000009472 formulation Methods 0.000 description 1
229960002737 fructose Drugs 0.000 description 1
235000015203 fruit juice Nutrition 0.000 description 1
239000008103 glucose Substances 0.000 description 1
235000011187 glycerol Nutrition 0.000 description 1
LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
239000003979 granulating agent Substances 0.000 description 1
238000005469 granulation Methods 0.000 description 1
230000003179 granulation Effects 0.000 description 1
230000002440 hepatic effect Effects 0.000 description 1
231100000086 high toxicity Toxicity 0.000 description 1
125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
238000011534 incubation Methods 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
238000010253 intravenous injection Methods 0.000 description 1
210000003734 kidney Anatomy 0.000 description 1
201000006370 kidney failure Diseases 0.000 description 1
SXQFCVDSOLSHOQ-UHFFFAOYSA-N lactamide Chemical class CC(O)C(N)=O SXQFCVDSOLSHOQ-UHFFFAOYSA-N 0.000 description 1
150000003893 lactate salts Chemical class 0.000 description 1
239000000787 lecithin Substances 0.000 description 1
235000010445 lecithin Nutrition 0.000 description 1
229940067606 lecithin Drugs 0.000 description 1
239000007788 liquid Substances 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
230000007774 longterm Effects 0.000 description 1
RDOIQAHITMMDAJ-UHFFFAOYSA-N loperamide Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(C(=O)N(C)C)CCN(CC1)CCC1(O)C1=CC=C(Cl)C=C1 RDOIQAHITMMDAJ-UHFFFAOYSA-N 0.000 description 1
229960001571 loperamide Drugs 0.000 description 1
210000001165 lymph node Anatomy 0.000 description 1
ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
239000001095 magnesium carbonate Substances 0.000 description 1
229910000021 magnesium carbonate Inorganic materials 0.000 description 1
235000014380 magnesium carbonate Nutrition 0.000 description 1
229940057948 magnesium stearate Drugs 0.000 description 1
201000004792 malaria Diseases 0.000 description 1
229960001855 mannitol Drugs 0.000 description 1
HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
229960004503 metoclopramide Drugs 0.000 description 1
TTWJBBZEZQICBI-UHFFFAOYSA-N metoclopramide Chemical compound CCN(CC)CCNC(=O)C1=CC(Cl)=C(N)C=C1OC TTWJBBZEZQICBI-UHFFFAOYSA-N 0.000 description 1
229940043348 myristyl alcohol Drugs 0.000 description 1
231100001091 no haematotoxicity Toxicity 0.000 description 1
235000014593 oils and fats Nutrition 0.000 description 1
239000004006 olive oil Substances 0.000 description 1
235000008390 olive oil Nutrition 0.000 description 1
229940051877 other opioids in atc Drugs 0.000 description 1
244000045947 parasite Species 0.000 description 1
230000003108 parasitologic effect Effects 0.000 description 1
239000002245 particle Substances 0.000 description 1
244000052769 pathogen Species 0.000 description 1
230000001717 pathogenic effect Effects 0.000 description 1
239000000312 peanut oil Substances 0.000 description 1
WXZMFSXDPGVJKK-UHFFFAOYSA-N pentaerythritol Chemical compound OCC(CO)(CO)CO WXZMFSXDPGVJKK-UHFFFAOYSA-N 0.000 description 1
229960005323 phenoxyethanol Drugs 0.000 description 1
229920000435 poly(dimethylsiloxane) Polymers 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
239000011118 polyvinyl acetate Substances 0.000 description 1
229920002689 polyvinyl acetate Polymers 0.000 description 1
239000000843 powder Substances 0.000 description 1
238000001556 precipitation Methods 0.000 description 1
150000003138 primary alcohols Chemical class 0.000 description 1
238000012545 processing Methods 0.000 description 1
238000000746 purification Methods 0.000 description 1
239000002464 receptor antagonist Substances 0.000 description 1
229940044551 receptor antagonist Drugs 0.000 description 1
230000000306 recurrent effect Effects 0.000 description 1
230000000241 respiratory effect Effects 0.000 description 1
238000012552 review Methods 0.000 description 1
235000019970 saccharin and its sodium salt Nutrition 0.000 description 1
150000004671 saturated fatty acids Chemical class 0.000 description 1
HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical class O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
239000008159 sesame oil Substances 0.000 description 1
235000011803 sesame oil Nutrition 0.000 description 1
238000007873 sieving Methods 0.000 description 1
239000000741 silica gel Substances 0.000 description 1
229910002027 silica gel Inorganic materials 0.000 description 1
RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
235000012239 silicon dioxide Nutrition 0.000 description 1
238000005245 sintering Methods 0.000 description 1
229910000029 sodium carbonate Inorganic materials 0.000 description 1
235000017550 sodium carbonate Nutrition 0.000 description 1
235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
YQDGWZZYGYKDLR-UZVLBLASSA-K sodium stibogluconate Chemical compound O.O.O.O.O.O.O.O.O.[Na+].[Na+].[Na+].O1[C@H]([C@H](O)CO)[C@H](O2)[C@H](C([O-])=O)O[Sb]21([O-])O[Sb]1(O)(O[C@H]2C([O-])=O)O[C@H]([C@H](O)CO)[C@@H]2O1 YQDGWZZYGYKDLR-UZVLBLASSA-K 0.000 description 1
229960001567 sodium stibogluconate Drugs 0.000 description 1
239000008279 sol Substances 0.000 description 1
239000000243 solution Substances 0.000 description 1
229960002920 sorbitol Drugs 0.000 description 1
239000000126 substance Substances 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
150000008163 sugars Chemical class 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
235000010487 tragacanth Nutrition 0.000 description 1
239000000196 tragacanth Substances 0.000 description 1
229940116362 tragacanth Drugs 0.000 description 1
150000003626 triacylglycerols Chemical class 0.000 description 1
208000037972 tropical disease Diseases 0.000 description 1
231100000397 ulcer Toxicity 0.000 description 1
235000021122 unsaturated fatty acids Nutrition 0.000 description 1
150000004670 unsaturated fatty acids Chemical class 0.000 description 1
235000019871 vegetable fat Nutrition 0.000 description 1
210000001835 viscera Anatomy 0.000 description 1
239000001993 wax Substances 0.000 description 1
239000010497 wheat germ oil Substances 0.000 description 1
239000000811 xylitol Substances 0.000 description 1
HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
235000010447 xylitol Nutrition 0.000 description 1
229960002675 xylitol Drugs 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/485—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Life Sciences & Earth Sciences (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Inorganic Chemistry (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Tropical Medicine & Parasitology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

SK986-2000A 1998-01-22 1998-01-22 Použitie miltefozínu na výrobu lieku a farmaceutická kombinácia na liečenie leishmanózy SK284839B6 (sk)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
PCT/EP1998/000345 WO1999037289A1 (en)	1998-01-22	1998-01-22	Solid pharmaceutical compositions containing miltefosine for oral administration in the treatment of leishmaniasis

Publications (2)

Publication Number	Publication Date
SK9862000A3 SK9862000A3 (en)	2000-11-07
SK284839B6 true SK284839B6 (sk)	2005-12-01

Family

ID=8166843

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SK986-2000A SK284839B6 (sk)	1998-01-22	1998-01-22	Použitie miltefozínu na výrobu lieku a farmaceutická kombinácia na liečenie leishmanózy

Country Status (24)

Country	Link
US (1)	US6544551B1 (cs)
EP (1)	EP1051159B1 (cs)
JP (1)	JP2002501015A (cs)
KR (1)	KR100517399B1 (cs)
CN (1)	CN100413492C (cs)
AT (1)	ATE215817T1 (cs)
AU (1)	AU756805B2 (cs)
BR (1)	BR9814772A (cs)
CA (1)	CA2318260C (cs)
CZ (1)	CZ299229B6 (cs)
DE (1)	DE69804865T2 (cs)
DK (1)	DK1051159T3 (cs)
ES (1)	ES2175663T3 (cs)
HU (1)	HUP0004363A3 (cs)
IL (1)	IL136196A (cs)
NO (1)	NO20003674D0 (cs)
NZ (1)	NZ505648A (cs)
PL (1)	PL189654B1 (cs)
PT (1)	PT1051159E (cs)
SI (1)	SI1051159T1 (cs)
SK (1)	SK284839B6 (cs)
TR (1)	TR200001717T2 (cs)
UA (1)	UA68372C2 (cs)
WO (1)	WO1999037289A1 (cs)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE10203195A1 (de) *	2002-01-25	2003-08-07	Zentaris Ag	Verwendung von Alkylphosphocholinen in der Präventivbehandlung von Protozoenerkrankungen
US7887817B2 (en) *	2002-01-25	2011-02-15	Aeterna Zentaris Gmbh	Process for preventing protozoal diseases
AU2002346284A1 (en) *	2002-04-26	2003-11-10	Rudolf Perl	Pharmaceutical compositions of phospholipid derivatives
US8383605B2 (en)	2002-07-30	2013-02-26	Aeterna Zentaris Gmbh	Use of alkylphosphocholines in combination with antimetabolites for the treatment of benign and malignant oncoses in humans and mammals
JP2005535688A (ja)	2002-07-30	2005-11-24	ツェンタリスゲゼルシャフトミットベシュレンクテルハフツング	抗腫瘍医薬との組合せにおけるアルキルホスホコリンの使用
WO2005023241A1 (en)	2003-09-09	2005-03-17	Fumapharm Ag	The use of fumaric acid derivatives for treating cardiac insufficiency, and asthma
SI2801354T1 (sl)	2004-10-08	2017-07-31	Forward Pharma A/S	Farmacevtske sestave z nadzorovanim sproščanjem, ki zajemajo ester fumarne kisline
US8703179B2 (en)	2006-05-11	2014-04-22	Kimberly-Clark Worldwide, Inc.	Mucosal formulation
WO2010020276A1 (en) *	2008-08-19	2010-02-25	Orphanidis Pharma Research Gmbh	Treatment of coccidian parasites
MX2011011596A (es)	2010-03-31	2012-02-01	Keryx Biopharmaceuticals Inc	Perifosina y capecitabina como un tratamiento combinado para cancer.
CA2818194A1 (en)	2010-11-22	2012-05-31	Dafra Pharma Research&Development Bvba	Solid dosage forms of oleyl phosphocholine
EP3616701A1 (en)	2011-06-24	2020-03-04	GRI Bio, Inc.	Prevention and treatment of inflammatory conditions
WO2014166941A1 (en) *	2013-04-08	2014-10-16	Academisch Medisch Centrum	Miltefosin or perifosin for use in the treatment of ibd
CA3018828C (en)	2014-09-17	2021-05-11	Steerlife India Private Limited	Effervescent composition and method of making it
CN104473941A (zh) *	2014-12-20	2015-04-01	长沙佰顺生物科技有限公司	一种含有米替福新的药物制剂及其制备方法
WO2017098481A1 (en)	2015-12-12	2017-06-15	Steerlife India Private Limited	Effervescent compositions of metformin and processes for preparation thereof
ES2989158T3 (es) *	2019-04-12	2024-11-25	Oblita Therapeutics Bvba	Formulaciones de dosificación en comprimidos de oleil fosfocolina

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE888444C (de) *	1951-11-10	1953-08-31	Benckiser Gmbh Joh A	Verfahren zum Tablettieren von hygroskopischen Praeparaten
IE59778B1 (en) *	1985-12-04	1994-04-06	Max Planck Gesellschaft	Medicament with anti-tumour action containing hexadecylphosphocholine
US4762658A (en) *	1986-10-08	1988-08-09	Central Soya Company, Inc.	Method of tableting of de-oiled phosphatides (lecithin)
EP0916343A1 (de) *	1989-09-27	1999-05-19	ASTA Medica Aktiengesellschaft	Verwendung von Alkylphosphorsäure-Verbindungen zur Bekämpfung von Psoriasis-Erkrankungen
US5290769A (en) *	1989-09-27	1994-03-01	Asta Pharma Aktiengesellschaft	Use of hexadecylphosphocholine for the treatment of psoriasis
DE4132344A1 (de) *	1991-09-27	1993-04-01	Max Planck Gesellschaft	Verfahren zur herstellung eines arzneimittels zur oralen oder topischen verabreichung bei der behandlung von leishmaniasis

1998
- 1998-01-22 ES ES98904121T patent/ES2175663T3/es not_active Expired - Lifetime
- 1998-01-22 EP EP98904121A patent/EP1051159B1/en not_active Expired - Lifetime
- 1998-01-22 SI SI9830205T patent/SI1051159T1/xx unknown
- 1998-01-22 CZ CZ20002596A patent/CZ299229B6/cs not_active IP Right Cessation
- 1998-01-22 CA CA002318260A patent/CA2318260C/en not_active Expired - Fee Related
- 1998-01-22 HU HU0004363A patent/HUP0004363A3/hu unknown
- 1998-01-22 WO PCT/EP1998/000345 patent/WO1999037289A1/en not_active Ceased
- 1998-01-22 DE DE69804865T patent/DE69804865T2/de not_active Expired - Lifetime
- 1998-01-22 PT PT98904121T patent/PT1051159E/pt unknown
- 1998-01-22 JP JP2000528271A patent/JP2002501015A/ja active Pending
- 1998-01-22 CN CNB988125714A patent/CN100413492C/zh not_active Expired - Fee Related
- 1998-01-22 KR KR10-2000-7008029A patent/KR100517399B1/ko not_active Expired - Fee Related
- 1998-01-22 AU AU62121/98A patent/AU756805B2/en not_active Ceased
- 1998-01-22 SK SK986-2000A patent/SK284839B6/sk unknown
- 1998-01-22 AT AT98904121T patent/ATE215817T1/de not_active IP Right Cessation
- 1998-01-22 UA UA2000084909A patent/UA68372C2/uk unknown
- 1998-01-22 TR TR2000/01717T patent/TR200001717T2/xx unknown
- 1998-01-22 NZ NZ505648A patent/NZ505648A/xx unknown
- 1998-01-22 BR BR9814772-2A patent/BR9814772A/pt not_active Application Discontinuation
- 1998-01-22 IL IL13619698A patent/IL136196A/en not_active IP Right Cessation
- 1998-01-22 PL PL98342838A patent/PL189654B1/pl not_active IP Right Cessation
- 1998-01-22 DK DK98904121T patent/DK1051159T3/da active
2000
- 2000-07-18 NO NO20003674A patent/NO20003674D0/no not_active Application Discontinuation
- 2000-07-24 US US09/624,890 patent/US6544551B1/en not_active Expired - Lifetime

Also Published As

Publication number	Publication date
CZ299229B6 (cs)	2008-05-21
NO20003674L (no)	2000-07-18
AU756805B2 (en)	2003-01-23
HUP0004363A3 (en)	2002-12-28
ES2175663T3 (es)	2002-11-16
IL136196A (en)	2004-07-25
PT1051159E (pt)	2002-09-30
AU6212198A (en)	1999-08-09
DK1051159T3 (da)	2002-08-05
NO20003674D0 (no)	2000-07-18
KR20010034311A (ko)	2001-04-25
CN100413492C (zh)	2008-08-27
TR200001717T2 (tr)	2000-11-21
SK9862000A3 (en)	2000-11-07
NZ505648A (en)	2002-10-25
HUP0004363A2 (hu)	2001-04-28
BR9814772A (pt)	2000-10-24
CN1283111A (zh)	2001-02-07
EP1051159A1 (en)	2000-11-15
CZ20002596A3 (cs)	2000-10-11
PL342838A1 (en)	2001-07-16
DE69804865T2 (de)	2002-11-07
JP2002501015A (ja)	2002-01-15
IL136196A0 (en)	2001-05-20
KR100517399B1 (ko)	2005-09-28
EP1051159B1 (en)	2002-04-10
CA2318260A1 (en)	1999-07-29
PL189654B1 (pl)	2005-09-30
SI1051159T1 (en)	2002-10-31
WO1999037289A1 (en)	1999-07-29
UA68372C2 (en)	2004-08-16
ATE215817T1 (de)	2002-04-15
US6544551B1 (en)	2003-04-08
DE69804865D1 (de)	2002-05-16
CA2318260C (en)	2006-11-21

Publication	Publication Date	Title
SK9862000A3 (en)	2000-11-07	Solid pharmaceutical compositions containing miltefosine for oral administration in the treatment of leishmaniasis
DE102004016947A1 (de)	2004-10-21	Feste pharmazeutische Zusammensetzung
DE60024491T2 (de)	2006-08-10	Schnell-wirkende, gefrier-trocknete, orale, pharmazeutische formulierung für die behandlung von migräne
DE69418252T2 (de)	1999-11-04	Stabilisierte, feste pharmazeutische Zubereitung, die Dextromethorphan Phenylpropanolamine und Coffein enthält
DE3915347A1 (de)	1989-11-16	Harzadsorbat und verfahren zu seiner herstellung
US4588589A (en)	1986-05-13	Antidiarrheal compositions and use thereof
DE3346525A1 (de)	1985-07-04	Pharmazeutische zubereitung mit speziellen 1,2-diacyl-glycero-3-phosphocholinen zur behandlung von erkrankungen im magen-darmbereich
DE69837450T2 (de)	2007-08-23	Alendronate zur Behandlung von Osteoporose
SK281193B6 (sk)	2001-01-18	Tableta so zlepšenou biodostupnosťou účinnej látky, kyseliny klodrónovej, spôsob jej výroby a použitie mikrokryštalickej celulózy
US20020107183A1 (en)	2002-08-08	Pharmaceutical preparations comprising cyclosporin for oral administration
DE3517820A1 (de)	1986-11-20	Pharmazeutische praeparate mit antihypertensiver und kardioprotektiver wirkung
US6194401B1 (en)	2001-02-27	Pharmaceutical compositions containing cyclosporine and a carrier comprising at least an ester of α-glycerophosphoric acid
US20050069584A1 (en)	2005-03-31	Diphenhydramine tannate solid dose compositions and methods of use
DE69916326T2 (de)	2005-03-17	Medizinische zusammensetzungen zur behandlung von knochenschäden im multiplen myelom
CZ79593A3 (en)	1994-01-19	Antitussive preparation
JPS58208231A (ja)	1983-12-03	コレカルシフエロ−ル誘導体含有薬剤
BG64968B1 (bg)	2006-11-30	Твърди фармацевтични състави, съдържащи милтефозин за орално приложение при лечението на leishmaniasis
MXPA00005298A (en)	2001-07-03	Solid pharmaceutical compositions containing miltefosine for oral administration in the treatment of leishmaniasis
EP1161241B1 (de)	2005-12-07	Stabile pharmazeutische anwendungsform für paroxetin-anhydrat
SK8702001A3 (en)	2002-01-07	Cyclosporin solution
HK1033434A (en)	2001-08-31	Solid pharmaceutical compositions containing miltefosine for oral administration in the treatment of leishmaniasis
HU181913B (en)	1983-11-28	Process for preparing synergetic pharmaceutical composition with skeleton muscle relaxing activity
US3786157A (en)	1974-01-15	Method of treating hyperglycemia
NZ246606A (en)	1995-09-26	Antimalarial compostions containing a synergistic combination of benflumetol and quinine or a derivative thereof